Pfizer’s US antitrust law play appears to have won the day, with Metsera choosing the less risky offer.
This approval marks a milestone for high-risk sMM patients, but analyst Biswajit Podder notes that there are caveats to its future success.
Rhythm’s stock dropped after the review period was extended, with the FDA asking for extra analyses.
SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD platform.
Pelthos is to pay $3m to Biofrontera and $1.2m to Ferrer upfront.
Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.
